Search

Showing total 96 results
96 results

Search Results

1. Letter: Shorter duration of intravenous terlipressin for variceal bleeding in patients with cirrhosis—A promising find.

2. Letter: Shorter duration of intravenous terlipressin for variceal bleeding in patients with cirrhosis—A promising find. Author's reply.

4. Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis—More evidence needed. Authors' reply.

5. Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis—More evidence needed.

6. Letter: Exploring the clinical utility of ammonia in critically ill patients with cirrhosis: More to do? Authors' reply.

9. Letter: 1‐kestose, the smallest fructooligosaccharide component, protection for mild to moderate ulcerative colitis patients—authors' reply.

13. Editorial: definition of factors associated with poor quality of life in patients with IBS—but where to from here? Authorsʼ reply.

19. Editorial: rectal hyposensitivity in patients with hypermobile Ehlers‐Danlos syndrome and constipation—authors' reply.

24. Editorial: choosing the optimal screening method for latent TB in patients with IBD commencing anti‐TNF‐therapy—authors' reply.

27. Editorial: bezafibrate in the treatment of patients with primary biliary cholangitis—are we there yet? Authors' reply.

30. Letter: screening for infectious side effects in patients with IBD—the importance and potential of real‐world remote monitoring.

31. Letter: patients who have both sarcopenia and frailty have similar prognosis to those with either condition separately—authors' reply.

32. Letter: patients who have both sarcopenia and frailty have similar prognosis to those with either condition separately.

33. Editorial: percutaneous placement of a permanent tunnelled catheter for patients with non‐malignant ascites ‐ is it safe? Authors' reply.

34. Editorial: 5‐ASA in IBD patients on biologics—'stop or continue'?

37. Letter: SARS‐CoV‐2 infection in two IBD patients treated with dual targeted therapy.

38. Letter: TIPSS improves muscle mass indices in patients with cirrhosis and severe portal hypertension – authors' reply.

39. Letter: screening for infectious side effects in patients with IBD—the importance and potential of real‐world remote monitoring. Authors' reply.

40. Editorial: risk of loss of response to anti TNFα in patients with inflammatory bowel diseases – the longer the less? Authors' reply.

41. Editorial: treating the liver to treat the kidney in non-alcoholic steatohepatitis.

42. Letter: ACE2, IBD and COVID‐19—why IBD patients may be at reduced risk of COVID‐19.

43. Letter: liver involvement and mortality in COVID‐19 patients – authors' reply.

44. Editorial: outcome prediction in patients with cirrhosis and acute‐on‐chronic liver failure—authors' reply.

45. Letter: does early transjugular intrahepatic porto‐systemic shunt really have no effect on survival in high‐risk patients with oesophageal variceal bleeding?

48. Letter: prevalence and patterns of gastrointestinal symptoms in a large Western cohort of patients with COVID‐19.

49. Letter: immunotherapy in IBD patients in a SARS‐CoV‐2 endemic area.